TREACE MEDICAL CONCEPTS, INC. TMCI 深 滬
已收盤 07-18 16:00:00 美东时间
5.65
-0.140
-2.42%
華盛通- 最 高6.105
- 今 開5.88
- 成交量 18.36万股
- 最 低 5.64
- 昨 收 5.79
- 總市值 3.55亿
- 52周最高 10.79
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 4.54
- 委 比 -66.65%
- 總股本 6290.50万
- 歷史最高 37.17
- 量 比 0.88
- 振 幅 8.03%
- 歷史最低 3.92
- 每 手 1
- 風險率 3.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Treace Medical Concepts Files Patent Infringement Lawsuit Against Zimmer Biomet And Paragon 28, Alleging Violation Of 4 Patents Related To Its Lapiplasty 3D Bunion Correction Technologies And Seeking Injunctive Relief And Damages
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its
06-06 01:05
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
<p>Treace Medical Concepts filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc., alleging infringement of four patents related to its Lapiplasty® 3D Bunion Correction® technologies. The case, filed in the U.S. District Court for the District of Delaware, seeks injunctive relief and damages. John T. Treace, the company's chairman, CEO, and founder, emphasized the importance of protecting their intellectual property to safeguar...
06-05 17:00
TMCI Lawsuit Alert! Class Action Lawsuit Against Treace Medical Concepts
Aclass actionlawsuit was filed againstTreace Medical Concepts...
05-23 20:10
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $10 to $8.6.
05-10 06:15
Treace Medical Concepts shares are trading lower following Q1 financial results.
Treace Medical Concepts shares are trading lower following Q1 financial results.
05-09 21:17
Treace Medical Concepts Affirms FY2025 Sales Guidance of $224.00M-$230.00M vs $227.53M Est
Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.00 million-$230.00 million to $224.00 million-$230.00 million vs $227.53 million estimate.
05-09 04:23
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
美股大行评级 | 潜在涨幅223.78%！内克塔治疗获杰富瑞升目标价至2美元，上调至"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调内克塔治疗(NKTR)评级至"买入"，目标价从1美元升至2美元</p> <p>• Roth MKM：维持Lovesac Co.(LOVE)"买入"评级，目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
Treace Medical Concepts names John Treace as chair
Treace Medical Concepts (NASDAQ:TMCI) said it has appointed John Treace, CEO and founder of Treace, as its chair, effective immediately following the 2025 annual meeting of stockholders. Treace will s...
04-07 20:31
